OMT-28 in Patients With Primary Mitochondrial Disease (PMD) (PMD-OPTION)

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

May 22, 2023

Primary Completion Date

March 30, 2025

Study Completion Date

June 30, 2025

Conditions
Primary Mitochondrial Disease
Interventions
DRUG

OMT-28

once daily

Trial Locations (9)

20133

IRCCS Istituto Neurologico Carlo Besta, SC Servizio Di Medicina Di Laboratorio - Genetica Medica E Neurogenetica, Via Celoria 11, Milan

40139

IRCCS Institute of Neurological Science of Bologna, University of Bologna, Department of Biomedical and Neuromotor Science (DIBINEM), Ospedale Bellaria Via Altura, 3, Bologna

53127

Universitätsklinikum Bonn, Sektion Neuromuskuläre Erkrankungen, Klinik und Poliklinik für Neurologie, Venusberg-Campus 1, Gebäude 80, NPP, Bonn

56126

Azienda Ospedaliero Universitaria Pisana, P.O. Santa Chiara, U.O. Neurologia, Edificio 13, Via Roma 67, Pisa

80336

Friedrich-Baur-Institut an der Neurologischen Klinik und Poliklinik, Klinikum der Universität München, Ludwig-Maximilians-Universität (LMU Klinikum), Ziemssenstr. 1a, Munich

98125

U.O.C. di Neurologia e Malattie Neuromuscolari, Messina

06120

Medizinisch Fakultät der Martin-Luther-Universität Halle-Wittenberg Universitätsklinik und Poliklinik für Neurologie Universitätsklinikum , Ernst-Grube-Str. 40, Halle

8-00168

UOC di neurofisiopatologia, Roma

6500 HB

Radboud University Nijmegen Medical Centre, Nijmegen

Sponsors
All Listed Sponsors
lead

Omeicos Therapeutics GmbH

INDUSTRY